Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042917 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL1452738 | 0.98 | LMNA (0.47) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL5684624 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL20184160 | 0.82 | KDM4E (0.36) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL2041795 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL69939 | 0.81 | KDM4E (0.54) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL1452735 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| Water SCHEMBL335807 | 0.78 | KDM4E (0.52) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL6345905 | 0.78 | KDM4E (0.52) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL29113117 | 0.78 | KDM4E (0.52) | SMN1; SMN2LMNAKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108079938-A | There is the PERFORMANCE OF MODIFIED VERMICULITE adsorbent of absorption property to the orthophosphates in water body | 北京益清源环保科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4402138-B1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025131957-A1 | DIAZINONE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-1781911-A | Intermediate for producing novel pyrazine derivatives | TOYAMA CHEMICAL CO LTD (JP) | 2006-06-07 | — | — | CN | disclosed |
| CN-1239511-C | Novel pyrazine derivative or salt thereof, and pharmaceutical composition containing the same | TOYAMA CHEMICAL CO LTD (JP) | 2006-02-01 | — | — | CN | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| EP-1440075-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2004-07-28 | — | — | EP | disclosed |
| CN-1418220-A | Novel pyrazine derivative or salt thereof, pharmaceutical composition containing same, and intermediate for producing both | TOYAMA CHEMICAL CO LTD (JP) | 2003-05-14 | — | — | CN | disclosed |
| WO-2003037904-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2003-05-08 | — | — | WO | disclosed |
| CN-1300279-A | Modulators of protein tyrosine phosphatases | NOVO NORDISK AS (DK) | 2001-06-20 | — | — | CN | disclosed |
| EP-0267740-A1 | Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof | SCHERING CORPORATION (US) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | SMN1; SMN2 2064/4885LMNA 2257/4885KDM4E 1214/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | SMN1; SMN2 2055/4885LMNA 3243/4885KDM4E 3268/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | SMN1; SMN2 2423/4885LMNA 2025/4885KDM4E 4548/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | SMN1; SMN2 2731/4885LMNA 1762/4885KDM4E 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.